LOXO-292 Reins In RET-Driven Tumors

Cancer Discov. 2018 Aug;8(8):904-905. doi: 10.1158/2159-8290.CD-NB2018-070. Epub 2018 Jun 2.

Abstract

LOXO-292, a selective and potent RET inhibitor, led to tumor shrinkage in RET fusion-positive and RET-mutant cancers alike, according to phase I data reported at the 2018 American Society of Clinical Oncology Annual Meeting.

Publication types

  • News